Table 3 Association between sociodemographic, clinical, treatment, and transplant characteristics on self-reported pulmonary outcomes.

From: Transplant characteristics and self-reported pulmonary outcomes in Swiss childhood cancer survivors after hematopoietic stem cell transplantation—a cohort study

 

Reporting of any pulmonary outcome

   
 

noutcome

Ntotal

%

OR

95% CI

p value*

Sociodemographic and lifestyle characteristics

      

Sex

     

0.795

 Male

13

69

19

1

  

 Female

13

63

21

1.12

0.47–2.64

 

Age at questionnaire, continuous (years)

26

132

20

1.05

0.99–1.11

0.088

Smoking statusa

     

0.924

Never smoking

12

60

20

1

  

Passive smoking

10

56

18

0.87

0.34–2.21

 

Former active smoking

2

9

22

1.14

0.21–6.21

 

Active smoking

2

7

29

1.60

0.27–9.28

 

Clinical characteristics

      

Age at diagnosis, continuous (years)

26

132

20

1.2

1.05–1.28

0.002

Follow-up time, continuous (years)

26

132

20

0.98

0.91–1.06

0.613

Era of diagnosis

     

0.800

 1976–1990

5

20

25

1

  

 1991–2000

8

45

18

0.64

0.18–2.31

 

 2001–2010

13

67

19

0.72

0.22–2.35

 

Cancer diagnosis according to ICCC-3

     

0.271

 Leukemia

15

72

21

1

  

 Lymphoma

5

20

25

1.27

0.39–4.04

 

 Neuroblastoma

1

19

5

0.21

0.03–1.71

 

 Otherb

5

21

24

1.18

0.37–3.76

 

Treatment characteristics

      

Bleomycin

     

0.040

 No

22

124

18

1

  

 Yes

4

8

50

4.63

1.08–19.97

 

Busulfan

     

0.190

 No

16

95

17

1

  

 Yes

10

37

27

1.83

0.74–4.51

 

Nitrosureas (BCNU and CCNU)

     

0.107

 No

22

122

18

1

  

 Yes

4

10

40

3.03

0.79–11.65

 

Cyclophosphamide

     

0.844

 No

2

9

22

1

  

 Yes

24

123

20

0.84

0.16–4.34

 

Ifosfamide

     

0.596

 No

15

70

21

1

  

 Yes

11

62

18

0.79

0.33–1.88

 

Melphalan

     

0.281

 No

15

88

17

1

  

 Yes

11

44

25

1.62

0.67–3.91

 

Treosulfan

     

0.400

 No

24

126

19

1

  

 Yes

2

6

33

2.12

0.36–12.28

 

Alkylating agentsc

     

0.084

 ≤11,300 mg/m2

9

66

14

1

  

 >11,300 mg/m2

17

66

26

2.19

0.89–5.37

 

Radiotherapy to chest (including TBI)

     

0.165

 No

6

46

13

1

  

 Yes

20

86

23

2.02

0.75–5.45

 

Thoracic surgery

     

<0.001

 No

19

120

16

1

  

 Yes

7

12

58

7.44

2.13–25.92

 

Transplant characteristics

      

Remission status at transplantation

     

0.223

 First remission/primary refractory

12

75

16

1

  

 Relapsed disease

14

57

24

1.71

0.72–4.05

 

Type of transplantation

     

0.995

 Allogeneic

14

71

20

1

  

 Autologous

12

61

20

0.99

0.42–2.35

 

Stem cell donor

     

0.739

 Autologous

12

61

20

1

  

 HLA ident. sibling, matched (un)related donor

11

56

20

0.99

0.40–2.48

 

 HLA mismatched (un)related, haploidentical

3

15

20

1.02

0.25–4.19

 

Source of transplant (n = 66)d

     

0.933

 Bone marrow

7

34

21

1

  

 Peripheral blood

6

26

23

1.15

0.34–3.98

 

 Cord blood

1

6

17

0.77

0.08–7.71

 

Graft versus host disease (n = 71)d

     

0.449

 No

4

15

27

1

  

 Yes

10

56

18

0.59

0.16–2.27

 
  1. Results from univariable logistic regression analysis. N = 132, median age at study 18.4 years.
  2. BCNU Lomustine, CCNU Carmustine, HLA human leukocyte antigen, ICCC-3 International Classification of Childhood Cancer, 3rd edition, OR Odds ratio, TBI total body irradiation, CI confidence interval.
  3. *p value calculate by logistic regression (Wald test) for continuous and binary independent variables and by likelihood ratio test for independent variables with >2 categories.
  4. aActive and former active smoking assessed in adolescents and adults. Passive and never smoking assessed in children, adolescent and adults.
  5. bOther diagnostic groups include: malignant bone tumors (n = 7), tumors of the central nervous system (n = 6), soft tissue sarcomas (n = 4), germ cell tumors (n = 3), retinoblastoma (n = 1).
  6. cCumulative alkylating dose according to cyclophosphamide equivalent dose (CED); categorized in smaller or equal to the median or larger as the median cumulative dose.
  7. dIn survivors undergone allogeneic transplantation only.
Back to article page